PMID- 19963108
OWN - NLM
STAT- MEDLINE
DCOM- 20091215
LR  - 20211203
IS  - 1873-4456 (Electronic)
IS  - 0165-4608 (Linking)
VI  - 195
IP  - 2
DP  - 2009 Dec
TI  - Identification of chromosomal abnormalities relevant to prognosis in chronic 
      lymphocytic leukemia using multiplex ligation-dependent probe amplification.
PG  - 97-104
LID - 10.1016/j.cancergencyto.2009.06.020 [doi]
AB  - B-cell chronic lymphocytic leukemia (CLL) is characterized by a highly variable 
      clinical course. Characteristic genomic abnormalities provide clinically 
      important prognostic information. Because karyotyping and fluorescence in situ 
      hybridization (FISH) are laborious techniques, we investigated the diagnostic 
      efficacy of the more recently developed multiplex ligation-dependent probe 
      amplification (MLPA) technique. MLPA and interphase FISH data of 88 CLL patients 
      were compared for loci encompassing the 13q14 region, chromosome 12, and the ATM 
      (11q22) and TP53 (17p13) genes. We found a perfect correlation, provided that the 
      abnormal clone was present in at least 10-20% of the cells. Because multiple loci 
      and multiple probes per locus were included in the MLPA assay, additional 
      abnormalities not covered by the FISH probes were detected. Furthermore, in 13 
      cases deletions partly covering the 13q14.3 locus were observed, including three 
      deletions that remained undetected by FISH. All the deletions included the 
      noncoding RNA locus DLEU1 (previously BCMS), which is considered to be the most 
      likely CLL-associated candidate tumor suppressor gene within the 13q14 region. We 
      conclude that MLPA serves as a comprehensive and reliable technique for the 
      simultaneous identification of different clinically relevant and region-specific 
      genomic aberrations in CLL.
FAU - Stevens-Kroef, Marian
AU  - Stevens-Kroef M
AD  - Department of Human Genetics, Radboud University Nijmegen Medical Center, PO Box 
      9101, 6500 HB Nijmegen, The Netherlands. m.stevens@antrg.umcn.nl
FAU - Simons, Annet
AU  - Simons A
FAU - Gorissen, Hanneke
AU  - Gorissen H
FAU - Feuth, Ton
AU  - Feuth T
FAU - Weghuis, Daniel Olde
AU  - Weghuis DO
FAU - Buijs, Arjan
AU  - Buijs A
FAU - Raymakers, Reinier
AU  - Raymakers R
FAU - Geurts van Kessel, Ad
AU  - Geurts van Kessel A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Genet Cytogenet
JT  - Cancer genetics and cytogenetics
JID - 7909240
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 0 (Tumor Suppressor Proteins)
RN  - EC 2.7.11.1 (ATM protein, human)
RN  - EC 2.7.11.1 (Ataxia Telangiectasia Mutated Proteins)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Ataxia Telangiectasia Mutated Proteins
MH  - Cell Cycle Proteins/genetics
MH  - *Chromosome Aberrations
MH  - Chromosomes, Human, Pair 13
MH  - DNA-Binding Proteins/genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Karyotyping
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*genetics
MH  - Ligase Chain Reaction
MH  - Prognosis
MH  - Protein Serine-Threonine Kinases/genetics
MH  - Reproducibility of Results
MH  - Tumor Suppressor Protein p53/genetics
MH  - Tumor Suppressor Proteins/genetics
EDAT- 2009/12/08 06:00
MHDA- 2009/12/16 06:00
CRDT- 2009/12/08 06:00
PHST- 2009/05/05 00:00 [received]
PHST- 2009/06/17 00:00 [revised]
PHST- 2009/06/20 00:00 [accepted]
PHST- 2009/12/08 06:00 [entrez]
PHST- 2009/12/08 06:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - S0165-4608(09)00336-7 [pii]
AID - 10.1016/j.cancergencyto.2009.06.020 [doi]
PST - ppublish
SO  - Cancer Genet Cytogenet. 2009 Dec;195(2):97-104. doi: 
      10.1016/j.cancergencyto.2009.06.020.